Healthcare Realty Trust Inc (HR) Stock Analysis and Metrics

Healthcare Realty Trust

NYSE: HR

$21.42 ▲ +0.28 (+1.30%)

At close: Jul 24, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap7.33 Bn

P/S5.04

Div. Yield0.06

Total Debt (Qtr)4.10 Bn

Add ratio to table…

About

Healthcare Realty Trust Incorporated is a self managed and self administered real estate investment trust that owns, leases, manages, acquires, finances, develops and redevelops income producing real estate properties associated primarily with the delivery of outpatient healthcare services throughout the United States. As of December 31, 2025, the company reported gross investments of approximately $10.3 billion across 502 consolidated properties, with a weighted average ownership interest of about 30% in 61 unconsolidated joint venture properties. The portfolio consisted mainly of medical office and outpatient facilities representing $9.3 billion of investment, complemented by inpatient, office, land held for development, financing receivables, financing lease right of use assets and corporate property. Medical office and outpatient properties accounted for roughly 90% of the total investment, while inpatient facilities represented a smaller but fully occupied segment. Overall occupancy stood at 90.4% of rentable square footage across the consolidated portfolio. The company provided leasing and property management services to approximately 93% of its properties nationwide, indicating a high level of internal management. Geographic diversification is present, with properties spread across multiple states, though the filing does not break down exact state allocations here. The company’s strategy emphasizes acquiring assets located on or near acute care hospital campuses to capture synergies with health systems. By maintaining a blend of ownership and joint venture interests, Healthcare Realty balances control with capital efficiency. This overview captures the scale and focus of the firm’s real estate holdings as of the end of 2025.

The company generates revenue primarily from rental income collected under leases for its medical office and outpatient properties. In addition, it earns fees from providing leasing and property management services to tenants, which it reported as covering about 93% of its portfolio as of year end 2025. Interest income from financing receivables, including those related to sale leaseback transactions, contributes to earnings as well. The company also realizes cash inflows from the disposition of properties; in 2025 it sold 70 assets for approximately $1.1 billion, generating roughly $1.0 billion of net cash after closing costs and adjustments. Proceeds from dispositions are often recycled into acquisitions, debt repayment or returned to shareholders through dividends. Capital allocated to development and redevelopment activities totaled $136.6 million during 2025, supporting the creation of future income producing assets. Development projects typically involve ground up construction or substantial renovation of existing buildings to meet tenant specifications. Redevelopment efforts may include repositioning older properties to attract higher quality tenants or to change the use mix. The weighted average capitalization rate for the 2025 dispositions was 6.7%, calculated as in place cash net operating income divided by sales price. Revenue streams are thus diversified across recurring rents, service fees, interest, and episodic gains from asset sales. This mix aims to provide stable cash flow while allowing for growth through reinvestment.

Healthcare Realty Trust Incorporated holds a prominent position among owners of medical office real estate, competing with private investors, healthcare providers, other REITs, real estate partnerships, and financial institutions for acquisitions and development. Its competitive advantages derive from a deliberate focus on facilities situated on or near acute care hospital campuses, which allows tenants to benefit from favorable Medicare reimbursement rates. The company concentrates investments in high growth markets and maintains a diversified tenant mix that encompasses more than 30 physician specialties along with surgery, imaging, cancer and diagnostic centers. This strategy aims to produce stable, growing income while lowering the long term risk profile of its property portfolio. Scale matters, as the firm’s $10.3 billion gross investment provides bargaining power with sellers and access to capital markets at favorable terms. Expertise in property management and leasing enables the company to achieve high occupancy levels, consistently above 90% in recent years. Relationships with major health systems often lead to preferential access to new development opportunities on hospital campuses. The firm’s internal capabilities reduce reliance on third party operators. The combination of a focused niche, geographic dispersion, and active management differentiates Healthcare Realty from more generalized real estate investors.

The company serves a varied base of medical tenants, including physician groups, outpatient clinics, surgery centers, imaging and diagnostic facilities, and cancer treatment providers. No single tenant accounted for 10% or more of the company’s consolidated revenues in 2025, reflecting a broadly dispersed customer base. Tenants operate across numerous specialties such as cardiology, orthopedics, dermatology, gastroenterology, and many others, ensuring that reliance on any one specialty or provider type is limited. This diversity helps to insulate the firm’s rental income from downturns affecting any particular segment of the healthcare industry. Lease terms typically run several years, with a weighted average remaining term of approximately 4.4 years as of the end of 2025, providing visibility into future cash flows. The tenant mix includes both national healthcare organizations and local physician practices, contributing to geographic and demographic resilience. By focusing on outpatient settings, Healthcare Realty aligns its assets with the ongoing shift of care delivery away from traditional inpatient hospitals. Overall, the tenant base is characterized by stability, breadth, and a low concentration risk.

Investment Thesis

▲ Bull case

Healthcare Realty 2.0's organic growth engine is demonstrably stronger than historical norms, with Q1 2026 same-store NOI growth of 6.9% driven by 110 basis points of occupancy improvement, 4.2% cash leasing spreads, and a 93.5% retention rate, which the company explicitly states tracks above 5% when excluding portfolio optimization dilution, signaling a sustainable shift from the old 2%-3% Steady Eddie model that the market continues to undervalue given the 11x FFO multiple; this outperformance is further amplified by the company's focus on high-growth Sunbelt markets where health systems like Advocate Health (AA-rated) and Wellstar (A+-rated) are signing long-term leases with embedded annual escalators of 3% plus, creating a compounding effect on NOI that is not fully captured in current guidance due to the conservative nature of their capital allocation framework which excludes future accretive activities from forward-looking metrics.
The company's capital allocation discipline reveals multiple hidden levers for accretive growth beyond guidance, including a $400 million remaining stock buyback capacity at a weighted average price of $17.38 in Q1, which provides immediate FFO accretion when the stock trades below intrinsic value, and a KKR joint venture platform with initial cash yields exceeding 7% — well above the implied cap rate — that remains vastly underutilized at just 5% of total NOI, with Scott indicating capacity to allocate $50 million to $100 million of capital in 2026 alone, a move that could meaningfully boost NOI without increasing leverage given the JV structure's off-balance-sheet nature and the partner's demonstrated appetite for growth that was previously constrained by Healthcare Realty's balance sheet limitations.
Structural tailwinds in the outpatient medical sector are intensifying due to demographic shifts and care delivery trends, with Scott emphasizing the rapid growth of the 65-plus population and the unabated shift to outpatient settings as multi-year demand drivers, yet the market appears to be pricing in only transient strength; this is reinforced by Crowley's transaction market observations showing core assets trading at 5.5%-6% cap rates while Healthcare Realty is achieving going-in yields in the low 7s on core-plus assets like the Birmingham deal, indicating a persistent mispricing of the sector's risk-adjusted returns that the company is actively exploiting through selective acquisitions and redevelopments, particularly as supply growth remains well below historical averages at just 1% of inventory, creating a prolonged supply-demand imbalance that supports durable rental rate growth.
The redevelopment portfolio represents a significant and underappreciated source of NOI upside, with 23 properties currently 64% pre-leased and targeting a 10% average cash-on-cash yield through occupancy and rental rate improvements, yet the company reported a 900 basis point sequential gain in leased percentage during Q1 — including two new projects like the 100% pre-leased Tufts Medical Center-connected MOB in Boston — and Hull noted the SNO (Signed Not Occupied) pipeline of 490,000 square feet, nearly half of which is in the lease-up redevelopment bucket, suggesting that stabilization of these assets will drive meaningful same-store NOI growth in back-half 2026 and beyond as they roll into the same-store pool, a catalyst not reflected in current guidance which excludes future redevelopment completions.

Healthcare Realty 2.0's organic growth engine is demonstrably stronger than historical norms, with Q1 2026 same-store NOI growth of 6.9% driven by 110 basis points of occupancy improvement, 4.2% cash leasing spreads, and a 93.5% retention rate, which the company explicitly states tracks above 5% when excluding portfolio optimization dilution, signaling a sustainable shift from the old 2%-3% Steady Eddie model that the market continues to undervalue given the 11x FFO multiple; this outperformance is further amplified by the company's focus on high-growth Sunbelt markets where health systems like Advocate Health (AA-rated) and Wellstar (A+-rated) are signing long-term leases with embedded annual escalators of 3% plus, creating a compounding effect on NOI that is not fully captured in current guidance due to the conservative nature of their capital allocation framework which excludes future accretive activities from forward-looking metrics.
The company's capital allocation discipline reveals multiple hidden levers for accretive growth beyond guidance, including a $400 million remaining stock buyback capacity at a weighted average price of $17.38 in Q1, which provides immediate FFO accretion when the stock trades below intrinsic value, and a KKR joint venture platform with initial cash yields exceeding 7% — well above the implied cap rate — that remains vastly underutilized at just 5% of total NOI, with Scott indicating capacity to allocate $50 million to $100 million of capital in 2026 alone, a move that could meaningfully boost NOI without increasing leverage given the JV structure's off-balance-sheet nature and the partner's demonstrated appetite for growth that was previously constrained by Healthcare Realty's balance sheet limitations.
Structural tailwinds in the outpatient medical sector are intensifying due to demographic shifts and care delivery trends, with Scott emphasizing the rapid growth of the 65-plus population and the unabated shift to outpatient settings as multi-year demand drivers, yet the market appears to be pricing in only transient strength; this is reinforced by Crowley's transaction market observations showing core assets trading at 5.5%-6% cap rates while Healthcare Realty is achieving going-in yields in the low 7s on core-plus assets like the Birmingham deal, indicating a persistent mispricing of the sector's risk-adjusted returns that the company is actively exploiting through selective acquisitions and redevelopments, particularly as supply growth remains well below historical averages at just 1% of inventory, creating a prolonged supply-demand imbalance that supports durable rental rate growth.
The redevelopment portfolio represents a significant and underappreciated source of NOI upside, with 23 properties currently 64% pre-leased and targeting a 10% average cash-on-cash yield through occupancy and rental rate improvements, yet the company reported a 900 basis point sequential gain in leased percentage during Q1 — including two new projects like the 100% pre-leased Tufts Medical Center-connected MOB in Boston — and Hull noted the SNO (Signed Not Occupied) pipeline of 490,000 square feet, nearly half of which is in the lease-up redevelopment bucket, suggesting that stabilization of these assets will drive meaningful same-store NOI growth in back-half 2026 and beyond as they roll into the same-store pool, a catalyst not reflected in current guidance which excludes future redevelopment completions.

▼ Bear case

Healthcare Realty's Q1 2026 same-store NOI growth of 6.9% appears inflated by an easier year-over-year comparison, as Scott acknowledged having a tough Q1 2025 that ramped up significantly in later quarters, meaning the strong sequential improvement may not be sustainable and could reverse to more modest growth in subsequent quarters when lapping stronger prior-period results, a dynamic that undermines the credibility of anchoring to this quarter's outperformance as indicative of a new normalized growth trajectory, especially given the company's own guidance implies a deceleration to a 3.75%-4.75% full-year range despite the Q1 beat.
The company's reliance on health system tenants introduces concentration risk that is not adequately addressed in disclosures, as evidenced by the Atlanta leasing activity where 176,000 square feet were signed with Wellstar across six on-campus buildings, including a 59,000 square foot cancer center, and similar large deals in Charlotte and Charleston, which, while credit-enhanced, could lead to overexposure to a few counterparties; Scott's emphasis on health system relationships as a key focus area suggests strategic importance, but the lack of disclosure on tenant concentration metrics leaves investors unaware of whether a small number of health systems now drive a disproportionate share of leasing volume and NOI, potentially increasing vulnerability to shifts in hospital operating strategies or reimbursement pressures.
The capital allocation strategy, while disciplined, carries execution risk in the joint venture arena, as Scott admitted that the KKR joint venture had seen no growth over the prior couple of years due to Healthcare Realty's lack of balance sheet capacity despite KKR's desire to expand, implying that the promised $50 million-$100 million of accretive JV capital deployment in 2026 is contingent on both identifying suitable third-party assets and maintaining partnership alignment, a process that has historically stalled and may not materialize as expected, particularly if the partner's growth appetite wanes or if deal flow in the outpatient medical space does not meet yield expectations given Crowley's observation that core-plus assets are not meaningfully above 5.5%-6% cap rates.
The company's balance sheet maneuvering, including the new $400 million delayed draw term loan at SOFR plus 90 basis points (all-in ~4.8%) to refinance the $600 million August bond maturity, while presented as a derisking move, introduces refinancing risk and potential covenant constraints; Gabbay noted the plan to draw the loan in late July to repay the bond, but any delay in execution or deterioration in credit market conditions could force reliance on the line of credit at higher effective rates, and the extended $400 million of swaps locked at SOFR 3.3% through 2029, while attractive, assumes stable interest rate expectations that may not hold if Fed policy shifts unexpectedly, creating uncertainty around future debt service costs that could pressure FFO.
The push to sell core assets and recycle capital, while framed as accretive, risks eroding the portfolio's long-term quality and growth potential, as Scott acknowledged that core assets are pricing at 5.5%-6% cap rates and that selling them to reinvest in JVs or redevelopments depends on finding opportunities with going-in yields exceeding 7%, yet Crowley's transaction market comments indicate that core-plus isn't much above those levels, making it difficult to consistently source accretive deals without taking on additional risk, and the lack of clarity on how much core asset sales would be tolerated — beyond Scott's reference to tax gain capacity limits — leaves open the possibility of over-aggressive portfolio turnover that could undermine the stability traditionally associated with the medical office sector.

Healthcare Realty's Q1 2026 same-store NOI growth of 6.9% appears inflated by an easier year-over-year comparison, as Scott acknowledged having a tough Q1 2025 that ramped up significantly in later quarters, meaning the strong sequential improvement may not be sustainable and could reverse to more modest growth in subsequent quarters when lapping stronger prior-period results, a dynamic that undermines the credibility of anchoring to this quarter's outperformance as indicative of a new normalized growth trajectory, especially given the company's own guidance implies a deceleration to a 3.75%-4.75% full-year range despite the Q1 beat.
The company's reliance on health system tenants introduces concentration risk that is not adequately addressed in disclosures, as evidenced by the Atlanta leasing activity where 176,000 square feet were signed with Wellstar across six on-campus buildings, including a 59,000 square foot cancer center, and similar large deals in Charlotte and Charleston, which, while credit-enhanced, could lead to overexposure to a few counterparties; Scott's emphasis on health system relationships as a key focus area suggests strategic importance, but the lack of disclosure on tenant concentration metrics leaves investors unaware of whether a small number of health systems now drive a disproportionate share of leasing volume and NOI, potentially increasing vulnerability to shifts in hospital operating strategies or reimbursement pressures.
The capital allocation strategy, while disciplined, carries execution risk in the joint venture arena, as Scott admitted that the KKR joint venture had seen no growth over the prior couple of years due to Healthcare Realty's lack of balance sheet capacity despite KKR's desire to expand, implying that the promised $50 million-$100 million of accretive JV capital deployment in 2026 is contingent on both identifying suitable third-party assets and maintaining partnership alignment, a process that has historically stalled and may not materialize as expected, particularly if the partner's growth appetite wanes or if deal flow in the outpatient medical space does not meet yield expectations given Crowley's observation that core-plus assets are not meaningfully above 5.5%-6% cap rates.
The company's balance sheet maneuvering, including the new $400 million delayed draw term loan at SOFR plus 90 basis points (all-in ~4.8%) to refinance the $600 million August bond maturity, while presented as a derisking move, introduces refinancing risk and potential covenant constraints; Gabbay noted the plan to draw the loan in late July to repay the bond, but any delay in execution or deterioration in credit market conditions could force reliance on the line of credit at higher effective rates, and the extended $400 million of swaps locked at SOFR 3.3% through 2029, while attractive, assumes stable interest rate expectations that may not hold if Fed policy shifts unexpectedly, creating uncertainty around future debt service costs that could pressure FFO.
The push to sell core assets and recycle capital, while framed as accretive, risks eroding the portfolio's long-term quality and growth potential, as Scott acknowledged that core assets are pricing at 5.5%-6% cap rates and that selling them to reinvest in JVs or redevelopments depends on finding opportunities with going-in yields exceeding 7%, yet Crowley's transaction market comments indicate that core-plus isn't much above those levels, making it difficult to consistently source accretive deals without taking on additional risk, and the lack of clarity on how much core asset sales would be tolerated — beyond Scott's reference to tax gain capacity limits — leaves open the possibility of over-aggressive portfolio turnover that could undermine the stability traditionally associated with the medical office sector.

Peer Comparison

Companies in the REIT - Healthcare Facilities

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	WELL	Welltower Inc.	172.91 Bn	122.84	12.78	17.93 Bn
2	VTR	Ventas, Inc.	46.62 Bn	179.03	7.60	-
3	DOC	Healthpeak Properties, Inc.	15.34 Bn	69.22	-33.80	0.25 Bn
4	OHI	Omega Healthcare Investors Inc	15.14 Bn	23.22	12.25	0.43 Bn
5	AHR	American Healthcare REIT, Inc.	10.71 Bn	194.58	4.76	1.51 Bn
6	CTRE	CareTrust REIT, Inc.	9.45 Bn	28.24	199.40	0.50 Bn
7	HR	Healthcare Realty Trust Inc	7.33 Bn	-	5.04	4.10 Bn
8	SBRA	Sabra Health Care REIT, Inc.	5.09 Bn	36.93	17.13	0.04 Bn

Research Tools

Developers

About

Investment Thesis

Product and Service Breakdown of Revenue (2025)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Product and Service Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password